Synthesis of oxirane from quinones against T. cruzi [PDF]
Chagas disease is an endemic disease caused by T. cruzi. Approximately 16 to 18 million people are infected and 50000 individuals die every year from this disease. Only two drugs have been used since the 70s: nifurtimox and benznidazole. Several synthetic substances continue to be reported in the literature, 2a,b but none of them become a new drug for ...
Paula F. Carneiro +6 more
openaire +2 more sources
NFATc1 mediates Toll-like receptor-independent innate immune responses during Trypanosoma cruzi infection. [PDF]
Host defense against the intracellular protozoan parasite Trypanosoma cruzi depends on Toll-like receptor (TLR)-dependent innate immune responses. Recent studies also suggest the presence of TLR-independent responses to several microorganisms, such as ...
Hisako Kayama +11 more
doaj +1 more source
Trypanosoma cruzi infection in neotropical wild carnivores (Mammalia: Carnivora): at the top of the T. cruzi transmission chain. [PDF]
Little is known on the role played by Neotropical wild carnivores in the Trypanosoma cruzi transmission cycles. We investigated T. cruzi infection in wild carnivores from three sites in Brazil through parasitological and serological tests.
Fabiana Lopes Rocha +10 more
doaj +1 more source
CD8+ T cells in Trypanosoma cruzi infection [PDF]
CD8(+) T cells have emerged as crucial players in the control of a number of protozoan pathogens, including Trypanosoma cruzi, the agent of human Chagas disease. The recent identification of the dominant targets of T. cruzi-specific T cells has allowed investigators to follow the generation of and document the functionality of T cell responses in both ...
Angel M, Padilla +2 more
openaire +2 more sources
Biotherapic T. cruzi 17DH when continuously used clinically improves mice infected with T. cruzi.
Introduction: In Trypanosoma cruzi infection, the pathogenesis is the result of a rupture in the host - parasite relationship [1]. This rupture is related to the imbalance of the vital force of the host, expressed through signs and symptoms, defined by Hahnemann (1995)[2] as being the source of the disease.
Denise Lessa Aleixo +6 more
openaire +2 more sources
Trypanosoma cruzi: ancestral genomes and population structure
Although the genome of Trypanosoma cruzi has been completely sequenced, little is known about its population structure and evolution. Since 1999, two major evolutionary lineages presenting distinct epidemiological characteristics have been recognised: T.
Sérgio DJ Pena +2 more
doaj +1 more source
Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses. [PDF]
BACKGROUND:Chagas disease is the highest impact parasitic disease in Latin America. We have proposed that changes in Trypanosoma cruzi-specific immune responses might serve as surrogate indicators of treatment success. Herein, we addressed in a long-term
María G Alvarez +9 more
doaj +1 more source
Background Trypanosoma conorhini and Trypanosoma rangeli, like Trypanosoma cruzi, are kinetoplastid protist parasites of mammals displaying divergent hosts, geographic ranges and lifestyles. Largely nonpathogenic T. rangeli and T.
Katie R Bradwell +12 more
doaj +1 more source
High Trypanosoma spp. diversity is maintained by bats and triatomines in Espírito Santo state, Brazil [PDF]
The aim of this study was to reevaluate the ecology of an area in the Atlantic Forest, southeast Brazil, where Chagas disease (CD) has been found to occur.
Costa, Leonora Pires +10 more
core +2 more sources
The Ly49E receptor inhibits the immune control of acute Trypanosoma cruzi infection [PDF]
The protozoan parasite Trypanosoma cruzi circulates in the blood upon infection and invades various cells. Parasites intensively multiply during the acute phase of infection and persist lifelong at low levels in tissues and blood during the chronic phase.
Almeida +48 more
core +2 more sources

